



PRESS RELEASE

## Successful results from the clinical trial for Kerasal Nail/Emtrix

STOCKHOLM, August 7<sup>th</sup> 2017, Moberg Pharma AB (OMX: MOB) reports positive clinical data for Kerasal Nail<sup>®</sup>/Emtrix<sup>®</sup>. The study shows that Kerasal Nail<sup>®</sup>/Emtrix<sup>®</sup> produces a visible improvement after just one week for nails affected by onychomycosis and/or nail psoriasis. The results will be presented at EADV Geneva in September 2017, as well as being published in the journal *Dermatology* and is now available online at <http://www.karger.com/DOI/10.1159/000478257>.

The early effects of treatment with Kerasal Nail<sup>®</sup>/Emtrix<sup>®</sup> (K101-03) on nails affected by onychomycosis and/or nail psoriasis were investigated in an open-label, multicenter clinical trial of 103 patients. The results show that as many as 76% of patients experienced a visible improvement after just one week, a figure which rose to 92% after eight weeks; this is the study's primary endpoint. In the group with nail psoriasis, 94% of the patients showed visible improvement after eight weeks.

*"The successful results from patients with nail psoriasis, and for the study as a whole, make a stronger selling point for Kerasal Nail<sup>®</sup>/Emtrix<sup>®</sup>, something which is of great importance for future efforts in all markets,"* says Peter Wolpert, CEO of Moberg Pharma.

The clinical trial was carried out at eight study sites in Italy in 2016. The results will be presented at the European Academy of Dermatology and Venerology Congress (EADV) in Geneva on September 13–17, 2017 and are being published now in the journal *Dermatology* under the title *Early visible improvements during K101-03 treatment: an open-label multicenter clinical investigation in patients with onychomycosis and/or nail psoriasis*.

### For additional information, please contact:

Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail: [peter.wolpert@mobergpharma.se](mailto:peter.wolpert@mobergpharma.se)

Anna Ljung, CFO, telephone: +46 707 66 60 30, E-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

### About this information

The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. (CET) on August 7<sup>th</sup> 2017.

### About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal<sup>®</sup>, Kerasal Nail<sup>®</sup>, Balmex<sup>®</sup>, New Skin<sup>®</sup>, Dermoplast<sup>®</sup>, Domeboro<sup>®</sup> and Fiber Choice<sup>®</sup>. Kerasal Nail<sup>®</sup> (Emtrix<sup>®</sup>, Zanmira<sup>®</sup> or Nalox<sup>™</sup> in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).